AU2803592A - Biocompatible implant for the timing of ovulation in mares - Google Patents
Biocompatible implant for the timing of ovulation in maresInfo
- Publication number
- AU2803592A AU2803592A AU28035/92A AU2803592A AU2803592A AU 2803592 A AU2803592 A AU 2803592A AU 28035/92 A AU28035/92 A AU 28035/92A AU 2803592 A AU2803592 A AU 2803592A AU 2803592 A AU2803592 A AU 2803592A
- Authority
- AU
- Australia
- Prior art keywords
- implant
- lhrh
- mares
- agonist
- biocompatible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 title claims description 57
- 230000016087 ovulation Effects 0.000 title claims description 25
- 239000000556 agonist Substances 0.000 claims description 23
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 20
- 108700025485 deslorelin Proteins 0.000 claims description 20
- 229960005408 deslorelin Drugs 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 5
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 210000002394 ovarian follicle Anatomy 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims 12
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims 12
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims 12
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 12
- 238000011282 treatment Methods 0.000 description 16
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108010037003 Buserelin Proteins 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
- 229960002719 buserelin Drugs 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003488 releasing hormone Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- YGGIRYYNWQICCP-LDRBRYNMSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylamino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydrox Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 YGGIRYYNWQICCP-LDRBRYNMSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- ZGKXAUIVGIBISK-SZMVWBNQSA-N Glu-His-Trp Chemical compound N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O ZGKXAUIVGIBISK-SZMVWBNQSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108700020627 fertirelin Proteins 0.000 description 1
- DGCPIBPDYFLAAX-YTAGXALCSA-N fertirelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 DGCPIBPDYFLAAX-YTAGXALCSA-N 0.000 description 1
- 229950001491 fertirelin Drugs 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 238000011419 induction treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 229960003822 lutrelin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Description
BIOCOMPATIBLE IMPLANT FOR THE TIMING OF OVULATION IN MARES FIELD OF THE INVENTION
The present invention relates to a method for controlling the timing of the ovulation of mares and to a biocompatible implant for use in such a method. BACKGROUND ART
The equine industry worldwide is continually improving breeding management. This improvement is driven by many factors; of significance are (i) the need to conserve "stallion power" and (ii) the veterinarians requirement to improve their efficiency by having mares ovulate with more predictability.
In order to achieve the above, the ability to predict, within predetermined time constraints when a mare will ovulate, is critical. The use of injection of human chorionic gonodotrophin (HCG) to stimulate ovulation in mares between 36-48 hours after application is widespread. However, despite success with this hormone, it has a number of serious drawbacks. They include:
(i) it is not registered for this use in many countries (USA, and areas of Europe) . Veterinarians using hCG in countries where it is unregistered are liable for any claims against failure of the product. (ii) continued used in the same mare can cause refractiveness - anaphylaxis is a possibility, (iii) hCG is derived from human urine either from pregnant or post menopausal women. Collection, isolation and purification are unpleasant, and the possibility of transmission of disease, particularly those of viral origin, is a risk, (iv) supplies of hCG cannot be guaranteed.
As an alternative to hCG, Leutinising Hormone Releasing Hormone (LHRH) has been injected into mares to stimulate ovulation. LHRH is also known as Gonodotrophin
releasing hormone (GnRH) . The LHRH stimulates the mare to produce its own gonodotrophin which, in turn, stimulates ovulation. An agonist of LHRH (Buserelin) has also been injected into mares and it has been reported that ovulation may be induced by such injections. Injected hormones must be typically administered a number of times to be successful and they are required in relatively large doses.
DISCLOSURE OF THE INVENTION The present invention is directed to an alternative method and composition for controlling the timing of ovulation in mares.
In a first aspect the present invention consists in a method for the controlled induction of ovulation in mares comprising implanting into a mare having a maturing ovarian follicle a solid biocompatible implant comprising a solid carrier and an effective amount of LHRH or an agonist of LHRH.
In a second aspect the present invention consists in a solid biocompatible implant for controlling the induction of ovulation in mares, the implant comprises a biologically absorbable solid and LHRH or an agonist of LHRH.
Deslorelin is a peptide and a super agonist for LHRH. It is the most preferred LHRH agonist for use in the present invention. The formula for Deslorelin is:- D-Trp6 Pro9 N Et LHRH (p Glu His Trp Ser Tyr D-Trp Leu Arg Pro NHEt)
Deslorelin has the particular advantage that its efficacy in the induction of ovulation in mares is sufficiently high that the biocompatible implant may be made small enough to be very acceptable in practice. There are however a number of other LHRH agonists which could be used in carrying out the present invention.
these include the following compounds as discussed in Dutton, A.S., "Luteinizing Hormone - Releasing Hormone (LHRH) Agonists", Drugs of the Future, Vol 13, No. 1, 1988s-
Agonist Structure Name (Company)
[D-Ser(But)6.des-Gly-NH2°]-LHRK(1-9)NHEt Buserelin (Hoec st) [D-Trp6]- HRH Tryptorelin (Debiopharm) (Decapeptyn)
Fertirelin (Takeda)
Histrelin (Ortho)
Leuproiide (Abbott)
Lutrelin (Wyeth)
Nafarelin (Syntex) [D-Ser(Bu')6, Azgly10)-LHRH Zoladex (Registered Trade Mark) ICI
In addition the following LHRH agonists may be used in carrying out the inventions- D-Ser(Bufc)6,]-LHRH(1-9)NHEt D-Lys(Boc)6,des-Gly-NH210]-LHRH(1-9)NHEt D-Glu(OBut)6,des-Gly-NH210]-LHRH(1-9)NHEt D-Asp(OBut)6,des-Gly-NH210]-LHRH(1-9)NHEt D-Leu6Ser(Bu )7,des-Gly-NH210]-LHRH(1-9) HEt D-Ser(But)6,Cys(But)7des-Gly-NH210]-LHRH(1-9) HEt D-Ser(But)6,Ser(But)7des-Gly-NH210]-LHRH(1-9)NHEt D-Phe6,Azgly10]-LHRH D-Tyr( e)6,Azgly λ°]-LHRH D-SerfBu1^6,Azgly10]-LHRH D-Tmo6]-LHRH D-Nal(2)6]-LHRH D-Ptf6]-LHRH D-Tmp6]-LHRH D-Bpal6]-LHRH D-Nal(2)6MeLeu7]-LHRH D-Nal(2)6MeLeu7,des-Gly-NH10]-LHRH-l-9NHEt
[D-hArg(Et2)6]-LHRH [D-hArg(Me,Bu)6]-LHRH
[D-hArg(Et,)6 Λdes-Gly-NH10]-LHRH-l-9NHEt [D-hArg(Me,Bu)D des-Gly-NH2 ]-LHRH-l-9NHEt The solid carrier for the LHRH or LHRH agonist should be a material into which the Deslorelin can be mixed or absorbed, onto which it may be adsorbed, or onto which it may be coated. It is a particularly preferred feature of the invention that the carrier is a biologically adsorbable inorganic salt such as calcium phosphate dihydrate, calcium phosphate, sodium sulphate or calcium carbonate. This allows the biocompatible implant to be made cheaply by a simple tableting technique. To assist in forming the implant and to provide an improved active release profile it is preferred that the implant contains a small proportion of an organic tablet release compound or lubricating agent such as a fatty acid or a hydrogenated vegetable oil. The tablet release compound preferably comprises from 4 to 10% by weight of the implant and more preferably about 8%. It has been found that the release characteristics of the LHRH agonist from such an inorganic salt mixed with such lubricating agent is such that ovulation can be induced in a tightly controlled manner, i.e., that a high proportion of the mares will ovulate at a given time after the administration of the implant. The implant is desirably as small as possible. Preferably the implant is substantially cylindrical having a diameter of from 0.5 to 5mm and a length of from 1 to 6mm. Obviously other sizes and shapes of biocompatible implants may be used however the selection of preferred embodiments of the present invention allows the size of the implant to be sufficiently small to be of practical utility. The implant is preferably small enough to be able to be implanted into a mare through a tubular needle. The
needle is inserted into the mare, such as in the neck region, and the implant pushed down the needle with an obturator as the needle is withdrawn. This leaves the implant embedded subcutaneously in the animal. The LHRH agonist is released from the implant in a controlled manner and the carrier is slowly dissolved.
The LHRH agonist should preferably be present in the implant in an amount of from 1.0 to 5.0mg, more preferably 1.5 to 3.Omg and most preferably 2.0 to 2.4mg for a thoroughbred mare of average size. BRIEF DESCRIPTION OF THE DRAWINGS
Hereinafter given by way of example only are preferred embodiments of the present invention described with reference to the accompanying figures in which:- Fig. 1 shows time to ovulation for mares treated as described in Example 1;
Fig. 2 shows time to ovulation after treatment with a short term implant containing 2.25mg of LHRH as described in Example 2; and Figs. 3 to 6 show ovulation response to treatments as described in Example 3. BEST METHOD FOR CARRYING OUT THE INVENTION
In all examples, unless indicated otherwise, short term implants of the LHRH agonist Deslorelin were prepared by mixing the Deslorelin with finely ground calcium carbonate and 5% of a hydrogenated vegetable oil tableting aid sold under the trade mark "LUBRITAB" (Edward Mendell Co. Inc, New York, U.S.A). The mixture is then tableted to the desired shape in a conventional manner. The implants were substantially cylindrical having a diameter of 2.3mm and a length of 3.4mm. All treatments with hCG were by injection. Example 1
Groups of twelve Hannovarian mares were each given a placebo implant, injected with either 3,000 iuhCG or with
5,000 iuhCG or given an implant containing 1.5mg of Deslorelin. In this example treatment was given when the mares showed follicles of 40mm diameter as the horses were Hannovarian. The results of this example are shown in Fig. 1. It can be seen that the 1.5mg Deslorelin implant performed as well as 3,000 iuhCG and possibly as well as 5,000 iuhCG. Example 2
The procedure of Example 1 was repeated with twenty seven Hannovarian mares being given a short term implant containing 2.25mg of Deslorelin. It can be assumed that those mares ovulating at 0-24 hours would have ovulated in the absence of treatment. The results obtained in this example are shown in Fig. 2. Example 3
Groups of mares were each given a placebo implant, a 1.3, 1.6 or 2.2mg Deslorelin implant, or 5,000 iuhCG. The placebo treatment is designated 101 in Fig." 6 and the Deslorelin implants are indicated, respectively, as 102, 104 and 100.
It can be seen that the variation in ovulation was less for the 2.2mg treatment than all other treatments; ovulation commonly occurred around 48 hours post-implantation with this treatment. Some data has been removed from the analyses as outlyers in this trial. The criteria for removal was: those animals ovulating within 24 hours or 8+ days after implantation were considered not to have been affected by the implant. The numbers removed were 2 x hCG; 5 x 100, 2 x 101, 0 x 102 and 2 x 104. Example 4
Mares with follicular size of at least 30mm, as determined by ultrasound and rectal palpation, were allocated to one of three treatment groups. They were 2.2mg Deslorelin implant, hCG (5000 iu) and untreated
controls. It can be seen that ovulation commonly occurred around 2 days for the Deslorelin implanted and hCG injected mares. Untreated controls took significantly longer to ovulate from both implantation and from the start of oestrus than the treated groups. It appears that the untreated controls were in oestrus longer than treated animals.
TABLE 1
STUDY 1: Mean values of oestrus characteristics for three ovulation induction treatments.
TREATMENTS
Characteristics LHRH hCG Control
No. day oestrus Day OV 30mm to OV
No. Ov's
Example 5
Mares with follicular size of at least 30mm, as determine by ultrasound and rectal palpation, at two locations (CSU and UCD) were allocated to one of five treatment groups. These treatment groups were a placebo implant, and implants containi 1.2mg, 1.7mg, 2.2mg and 2.7mg of Deslorelin. In this example implant comprised finely ground calcium phosphate dihydrate, 8 by weight Lubritab and, where appropriate, the Deslorelin. A summary of the results obtained is provided in Table 2 which shows the mean time in hours to ovulation, standard deviation hours of the time to ovulation, the number of mares in the sam and the percentage of mares ovulating within 48 hours.
Table 2
Summary statistics* for the time to ovulation by study locati and Deslorelin does treatment group.
UCD
♦Summary statistics include the mean (x) and standard deviation (s) of the time to ovulation, the sample size (n), and the percent of mares ovulating within 48 hours
The mares were mated and Table 3 summarises the pregnancy among the mares. This table provides the sample size, the number and percent of mares pregnant through a first cycle and the number and percent of mares pregnant through a second cycle.
Table 3
Summary* of pregnancy among study mares by study location and Deslorelin dose treatment group.
Treatment Group No. (Deslorelin dose, mσ)
1 2 3 4 5 Center (0) (1-2) (1.7) (2.2) (2.7)
* Summary includes the sample size (n) , the number (m.. ) and percent (P.) of mares pregnant through the first cycle, and the number (π ) and percent (P?) of mares pregnant through the second cycle. ** One mare in each of these study groups was not bred back.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims (17)
1. A method for the controlled induction of ovulation in mares comprising implanting into a mare having a maturing ovarian follicle a solid biocompatible implant comprising a solid carrier and an effective amount of LHRH or an agonist of LHRH.
2. A method as claimed in claim 1 in which the LHRH agonist is Deslorelin.
3. A method as claimed in claim 1 in which the LHRH agonist is present in the implant in an amount of from 1.0 to 5.0 mg.
4. A method as claimed in claim 3 in which the LHRH agonist is present in the implant in an amount of 1.5 to 3.0 mg.
5. A method as claimed in claim 4 in which the LHRH agonist is present in the implant in an amount of 2.0 to 2.4 mg.
6. A method as claimed in claim 1 in which the solid carrier comprises a biologically absorbable inorganic salt and an organic tablet release compound.
7. A method as claimed in claim 1 in which the implant is embedded subcutaneously into the mare.
8. A method as claimed in claim 7 in which the implant is embedded into the mare through a tubular needle inserted into the mare, the implant being pushed down the needle with an obturator as the needle is withdrawn.
9. A solid biocompatible implant for controlling the induction of ovulation in mares, the implant comprises a biologically absorbable solid and LHRH or an agonist of LHRH.
10. A biocompatible implant as claimed in claim 1 in which the LHRH agonist is Deslorelin.
11. A biocompatible implant as claimed in claim 9 in which the LHRH agonist is present in the implant in an amount of from 1.0 to 5.0 mg.
12. A biocompatible implant as claimed in claim 11 in which the LHRH agonist is present in the implant in an amount of from 1.5 to 3.0 mg.
13. A biocompatible implant as claimed in claim 11 in which the LHRH agonist is present in the implant in an amount of from 2.0 to 2.4 mg.
14. A biocompatible implant as claimed in claim 9 in which the solid carrier comprises a biologically absorbable inorganic salt and an organic tablet release compound.
15. A biocompatible implant as claimed in claim 14 in which the inorganic salt is selected from the group comprising calcium phosphate dihydrate, calcium phosphate, sodium sulphate and calcium carbonate.
16. A biocompatible implant as claimed in claim 14 in which the organic tablet release compound is selected from the group comprising a fatty acid and a hydrogenated vegetable oil.
17. A biocompatible implant as claimed in claim 9 in which the implant is substantially cylindrical having a diameter of from 0.5 to 5.0 mm and a length of from 1.0 to 6.0 mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU28035/92A AU659508B2 (en) | 1991-10-21 | 1992-10-19 | Biocompatible implant for the timing of ovulation in mares |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPK903791 | 1991-10-21 | ||
| AUPK9037 | 1991-10-21 | ||
| PCT/AU1992/000557 WO1993007833A1 (en) | 1991-10-21 | 1992-10-19 | Biocompatible implant for the timing of ovulation in mares |
| AU28035/92A AU659508B2 (en) | 1991-10-21 | 1992-10-19 | Biocompatible implant for the timing of ovulation in mares |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2803592A true AU2803592A (en) | 1993-05-21 |
| AU659508B2 AU659508B2 (en) | 1995-05-18 |
Family
ID=25620496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU28035/92A Expired AU659508B2 (en) | 1991-10-21 | 1992-10-19 | Biocompatible implant for the timing of ovulation in mares |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU659508B2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU586252B2 (en) * | 1985-05-10 | 1989-07-06 | University Of Melbourne, The | Induction of ovulation in mares |
-
1992
- 1992-10-19 AU AU28035/92A patent/AU659508B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU659508B2 (en) | 1995-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0609345B1 (en) | Biocompatible implant for the timing of ovulation in mares | |
| TWI405578B (en) | Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits | |
| JP2003517014A (en) | Pharmaceutical implant containing immediate release and sustained release components and administration method | |
| US5342622A (en) | Subdermal biocompatible implants | |
| US20110142901A1 (en) | Sustained release composition | |
| US5063204A (en) | Process for treating infertility | |
| AU701837B2 (en) | Novel formulation for peptide release | |
| EP0848954B1 (en) | Method for promoting ovulation and parturition in mammals | |
| AU659508B2 (en) | Biocompatible implant for the timing of ovulation in mares | |
| Schlegel | A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer. | |
| WO1987006828A1 (en) | Biocompatible implants | |
| EP1541168B1 (en) | Method of synchronising ovulation in cattle | |
| Fraser | GnRH and its analogues: current therapeutic applications and new prospects | |
| Furr et al. | Slow release formulation of ‘Zoladex’(ICI 118630) for the treatment of hormone responsive prostate and mammary tumours | |
| Sanders et al. | An injectable biodegradable controlled release delivery system for LHRH analogues | |
| AU1843899A (en) | Novel formulation for peptide release | |
| AU2005249143A1 (en) | Sustained release composition |